Abstract:
An alpha(1)-adrenergic receptor (alpha(1)-AR) antagonist increased heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), but it is unknown whether this adverse result was due to alpha(1)-AR inhibition